Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 20 Results

Title
Intervention Indication Therapeutic Area Year Actions
Triptorelin Pamoate (subcutaneous injection) for Prostate Cancer Triptorelin Pamoate (Decapeptyl) Prostate cancer Male Reproductive Cancer 2018 View  |  Download
Talazoparib in addition to enzalutamide for metastatic castration-resistant prostate cancer Enzalutamide (Xtandi; MDV3100) , Talazoparib (MDV3800; BMN-673; Talzenna; talazoparib tosylate) Prostate cancer Male Reproductive Cancer 2021 View  |  Download
Pembrolizumab with enzalutamide for treating
metastatic castration-resistant prostate cancer
Enzalutamide (Xtandi; MDV3100) , Pembrolizumab (Keytruda; MK-3475) Prostate cancer Male Reproductive Cancer 2022 View  |  Download
Pembrolizumab in combination with olaparib for anti-hormone and chemotherapy failure metastatic castration-resistant prostate cancer – third line Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) , Pembrolizumab (Keytruda; MK-3475) Prostate cancer Male Reproductive Cancer 2020 View  |  Download
Pembrolizumab in addition to docetaxel for chemotherapy-naive metastatic castration-resistant prostate cancer – second line Docetaxel (Taxotere; docetaxel trihydrate; docetaxel anhydrous) , Pembrolizumab (Keytruda; MK-3475) Prostate cancer Male Reproductive Cancer 2020 View  |  Download
Pembrolizumab (Keytruda) for metastatic castration‐resistant prostate Pembrolizumab (Keytruda; MK-3475) Prostate cancer Male Reproductive Cancer 2017 View  |  Download
Olaparib in addition to abiraterone for metastatic castration-resistant prostate cancer – First line Abiraterone acetate (Zytiga; Yonsa) , Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) Prostate cancer Male Reproductive Cancer 2020 View  |  Download
Olaparib for BRCAm or ATM mutated metastatic castration-resistant prostate cancer Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) Prostate cancer Male Reproductive Cancer 2019 View  |  Download
Nivolumab with docetaxel for advanced castration-resistant prostate cancer Docetaxel (Taxotere; docetaxel trihydrate; docetaxel anhydrous) , Nivolumab (Opdivo; BMS-936558; ONO-4538) Prostate cancer Male Reproductive Cancer 2021 View  |  Download
Nivolumab in combination with rucaparib for metastatic castration-resistant prostate cancer with prior chemotherapy Docetaxel (Taxotere; docetaxel trihydrate; docetaxel anhydrous) , Enzalutamide (Xtandi; MDV3100) , Nivolumab (Opdivo; BMS-936558; ONO-4538) , Rucaparib (Rubraca; PF-1367338) Prostate cancer Male Reproductive Cancer 2019 View  |  Download
1 2
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications